Dabigatran vs Edoxaban Side Effects
Both dabigatran and edoxaban have similar overall bleeding risks, but dabigatran causes significantly more dyspepsia (5-10% of patients), while edoxaban has a more favorable gastrointestinal tolerability profile. 1
Key Side Effect Differences
Gastrointestinal Effects
- Dabigatran: Causes dyspepsia, upset stomach, or burning abdominal pain in 5-10% of patients 1. This is a distinctive side effect related to its tartaric acid core and is clinically significant enough that dose reduction should be considered in patients with gastritis, esophagitis, or gastro-esophageal reflux 2
- Edoxaban: Does not have this dyspepsia issue. Common side effects include rash and abnormal liver function tests, but gastrointestinal upset is less prominent 3
Bleeding Profile
Real-world data shows nuanced differences:
Major bleeding: Recent large-scale studies demonstrate that dabigatran and edoxaban have comparable major bleeding rates 4, 5. However, when directly compared in network meta-analyses, edoxaban showed slightly higher bleeding risk than dabigatran 110mg but similar to dabigatran 150mg 6
Clinically relevant non-major bleeding: Dabigatran appears to have a modest advantage, with edoxaban showing 9% higher risk of major or clinically relevant non-major bleeding compared to dabigatran in head-to-head comparisons 4
Intracranial hemorrhage: Both agents reduce intracranial bleeding by approximately 50% compared to warfarin, with no significant difference between them 2
Other Notable Side Effects
Dabigatran-specific concerns:
- Indigestion and upset stomach are the dominant complaints
- Allergic reactions including hives, rash, and itching reported 1
- Requires consideration of gastric protection in susceptible patients
Edoxaban-specific concerns:
- Rash is more commonly reported 3
- Abnormal liver function tests occur more frequently 3
- Kidney and urinary system adverse events may be more prominent 7
- Anemia is common to both but may be slightly more frequent with edoxaban
Clinical Implications for Drug Selection
Choose dabigatran when:
- Patient has no history of dyspepsia or GERD
- Slightly lower bleeding risk is prioritized
- Patient is ≥80 years (110mg dose available) 2
Choose edoxaban when:
- Patient has history of dyspepsia, gastritis, or GERD
- Patient has moderate-severe renal impairment (CrCl 15-50 mL/min) - edoxaban has more straightforward dose reduction 2
- Patient is on interacting medications (ciclosporin, dronedarone, erythromycin, ketoconazole) where dose adjustment is clearly defined 2
- Once-daily dosing improves adherence
Important Caveats
The most recent real-world German data raised concerns about mortality with edoxaban versus phenprocoumon (a long-acting VKA), though this did not extend to dabigatran 8. However, this finding is specific to phenprocoumon comparison and should not override the established safety profiles from major trials and other real-world studies 4, 5.
Both agents share common DOAC risks:
- Bleeding remains the primary safety concern for both
- No antidote readily available for edoxaban (idarucizumab only reverses dabigatran) 1
- Both require dose adjustment in renal impairment, though criteria differ 2, 9
- Neither should be used in mechanical heart valves or moderate-to-severe mitral stenosis 2
The choice between these agents should prioritize gastrointestinal tolerability as the main differentiator, with dabigatran's dyspepsia being the most clinically impactful difference in side effect profiles.